DECNUPAZ is indicated for the treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN).¹

Remission in frontline BPDCN

Treatment-naïve BPDCN: 70% CR/CRc* rate (95% CI: 51.3–84.4; n/N=23/33). CADENZA was a multicenter, open-label, single-arm Phase 1/2 clinical trial evaluating DECNUPAZ 0.045 mg/kg IV once every 3 weeks in adults with treatment-naïve^† BPDCN with no CNS involvement or relapsed/refractory BPDCN without evidence of active CNS disease. ^1,2 Remission (CR/CRc) is defined as complete remission (CR) or complete remission with residual skin abnormality not indicative of active disease (CRc).¹

SELECT IMPORTANT SAFETY INFORMATION¹

BOXED WARNING: HEPATOTOXICITY, INCLUDING HEPATIC VENO-OCCLUSIVE DISEASE (VOD) (ALSO KNOWN AS SINUSOIDAL OBSTRUCTION SYNDROME) 

• ​​​​​​ VOD, a severe form of hepatotoxicity, has been reported in patients with BPDCN treated with DECNUPAZ, including severe or fatal hepatic VOD. 

• ​​​​Closely monitor for signs and symptoms of VOD. Monitor liver tests and total bilirubin prior to each dose. 

• ​​​​Discontinue DECNUPAZ for patients who experience VOD.

Please see additional Important Safety Information, including BOXED WARNING, below.

Introducing DECNUPAZ:
Durable remission in frontline BPDCN in an outpatient setting^1,2 

Dear Healthcare Provider,

CR=complete remission; CRc=clinical complete remission

Study design: CADENZA was a multicenter, open-label, single-arm Phase 1/2 clinical trial evaluating DECNUPAZ 0.045 mg/kg IV once every 3 weeks in adults with treatment-naïve^† BPDCN with no CNS involvement or relapsed/refractory BPDCN without evidence of active CNS disease.^1,2

*Remission (CR/CRc) is defined as complete remission (CR) or complete remission with residual skin abnormality not indicative of active disease (CRc).¹

^† Included patients with de novo BPDCN (n=22) and patients with prior or concomitant hematologic malignancy (n=11), with no CNS involvement.¹

^‡Kaplan-Meier estimate.¹

SELECT IMPORTANT SAFETY INFORMATION¹

Additional Warnings and Precautions

Infusion-related reactions, edema, sulfite allergic reactions, and embryo-fetal toxicity.

Adverse Reactions 

The most common adverse reactions (≥20%) were edema, fatigue, musculoskeletal pain, hemorrhage, infusion-related reactions, nausea, and diarrhea.

IMPORTANT SAFETY INFORMATION AND INDICATION¹

IMPORTANT SAFETY INFORMATION¹

BOXED WARNING: HEPATOTOXICITY, INCLUDING HEPATIC VENO-OCCLUSIVE DISEASE (VOD) (ALSO KNOWN AS SINUSOIDAL OBSTRUCTION SYNDROME)

• ​DECNUPAZ can cause hepatotoxicity, including severe or fatal hepatic VOD (also known as sinusoidal obstruction syndrome). 

• ​Closely monitor patients for signs and symptoms of VOD, including elevations in liver tests, hepatomegaly (which may be painful), rapid weight gain, and ascites. 

• ​Monitor liver tests, including ALT, AST, and total bilirubin, prior to each dose of DECNUPAZ. 

• ​ Delay DECNUPAZ dosage for liver test elevation. Permanently discontinue DECNUPAZ for patients who experience VOD.

WARNINGS AND PRECAUTIONS

Hepatotoxicity, Including Hepatic VOD

• ​ DECNUPAZ can cause hepatotoxicity, including VOD, a severe form of hepatotoxicity. In CADENZA, VOD occurred in 6% (7/116) of adult patients during treatment or following a subsequent hematopoietic stem cell transplantation (HSCT). Of the 7 total patients that developed VOD, 3 patients had treatment-naïve BPDCN and 4 patients had relapsed/refractory BPDCN. Among all 116 patients treated with DECNUPAZ at 0.045 mg/kg, VOD occurred in 2/116 (2%) during treatment, with onset up to 30 days after the last dose. Among 19 patients with BPDCN who proceeded to HSCT, VOD occurred in 5/19 patients (26%), including 2 fatal cases. The median time from subsequent HSCT to onset of VOD was 11 days (range: 7-25 days).

• ​After receiving DECNUPAZ, patients should be closely monitored for signs and symptoms of VOD, including elevations in ALT, AST, and total bilirubin; hepatomegaly (which may be painful); rapid weight gain; and ascites. Monitor liver tests, including ALT, AST, and total bilirubin, prior to each dose of DECNUPAZ. Based on elevations of liver tests, delay DECNUPAZ. In patients who experience VOD, discontinue DECNUPAZ and treat according to standard medical practice. 

Infusion-Related Reactions

• ​ DECNUPAZ can cause serious, life-threatening infusion-related reactions (IRR); signs and symptoms of IRR include dyspnea, flushing, fever, chills, nausea, chest discomfort, hypotension, and vomiting. In CADENZA, IRR occurred in 26% (30/116) of patients during treatment with DECNUPAZ at 0.045 mg/kg once every 3 weeks, including Grade 1 in 4.3% (5/116), Grade 2 in 16% (19/116), and Grade 3 in 5% (6/116) of patients. IRR occurred in Cycle 1 in 25% (29/116) of patients with decreasing frequency in subsequent cycles. IRR led to discontinuation in 1 patient.

• ​ Premedicate with a corticosteroid the day before infusion, and premedicate with a corticosteroid, antihistamine, and antipyretic prior to dosing. Premedication the day before infusion and prior to dosing led to reduced frequency and severity of IRR.

• ​Monitor patients closely for potential IRR during the infusion and for at least 4 hours, or longer as clinically indicated, after the first infusion and for at least 1 hour after subsequent infusions.

• ​ Interrupt infusion of DECNUPAZ and institute appropriate medical management if an infusion-related reaction occurs. Depending on the severity of the infusion-related reaction, reduce infusion rate or permanently discontinue. 

Edema

• ​ DECNUPAZ can cause edema and fluid retention, including serious events. In CADENZA, Grade 3-4 edema occurred in 16% (18/116) of patients treated with DECNUPAZ, including Grade 3-4 generalized edema in 2.6% (3/116) of patients. 

• ​ Monitor patients for new or worsening edema. For Grade 2 or 3 edema, delay further dosing of DECNUPAZ until edema has returned to Grades 0-1 or baseline. For Grade 3 edema or Grade 2 edema with dose delay for more than 2 weeks, consider resuming at a lower dose. For Grade 4 edema, permanently discontinue. Institute appropriate medical management for edema. 

Sulfite Allergic Reactions

• ​ DECNUPAZ contains sodium metabisulfite, a sulfite that may cause allergic-type reactions, including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in non-asthmatic people.

Embryo-Fetal Toxicity

• ​ Based on its mechanism of action, DECNUPAZ can cause embryo-fetal harm when administered to a pregnant woman because it contains a genotoxic compound (FGN849) and affects actively dividing cells.

• ​Advise patients of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment with DECNUPAZ and for 7 months after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with DECNUPAZ, and for 4 months after the last dose.

ADVERSE REACTIONS

• ​ Serious adverse reactions occurred in 55% of patients treated with DECNUPAZ. The most common (≥2%) serious adverse reactions were febrile neutropenia, pneumonia, edema, sepsis, hemorrhage, thrombosis, infusion-related reactions, viral infection, pneumonitis, infections without pathogens identified, pyrexia, and musculoskeletal pain. Fatal adverse reactions occurred in 4.3% of patients who received DECNUPAZ, including cardiac arrest (0.9%), clostridium difficile infection (0.9%), failure to thrive (0.9%), depressed level of consciousness (0.9%), and respiratory failure (0.9%).

• ​ The most common adverse reactions (≥20%) were edema, fatigue, musculoskeletal pain, hemorrhage, infusion-related reactions, nausea, and diarrhea. 

• ​The most common Grade 3 or 4 laboratory abnormalities (≥10%) were decreased neutrophils, decreased platelets, decreased lymphocyte count, decreased white blood cell count, decreased hemoglobin, and increased glucose. 

DRUG INTERACTIONS

• ​FGN849 is a substrate of CYP3A. Closely monitor patients for adverse reactions with DECNUPAZ when used concomitantly with strong and moderate CYP3A inhibitors.

USE IN SPECIAL POPULATIONS

• ​Lactation: Advise women not to breastfeed during treatment with DECNUPAZ and for 1 month after the last dose.
• ​Renal Impairment: Avoid use of DECNUPAZ in patients with moderate to severe renal impairment (CLcr <60 mL/min, estimated by Cockcroft-Gault) or patients with end-stage renal disease.
• ​Hepatic Impairment: Avoid use of DECNUPAZ in patients with moderate to severe hepatic impairment (total bilirubin >1.5 x ULN with any AST).

INDICATION¹

DECNUPAZ™ (pivekimab sunirine-pvzy) is indicated for the treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN).

© 2026 AbbVie. All rights reserved. 

DECNUPAZ and its design are trademarks of ImmunoGen, Inc., an AbbVie company.

US-PVEK-250129 June 2026